A Phase 2 interventional study of Ranolazine 500 mg in Atherosclerotic Coronary Vascular Disease, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 14 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Inability or unwillingness to participate in multiple exercise treadmill tests and/or any other requirements of this study as assessed by the Investigator.
Other protocol-defined inclusion/exclusion criteria may apply.
Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.
Drug: Ranolazine 500 mg
Ranolazine 500 mg, oral tablet, b.i.d.
Also known as: Ranexa®
Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index
ST/HR index was measured as the average change in ST segment depression relative to heart rate change over the entire duration of exercise, monitored by ECG during the exercise treadmill tests. Change in maximum ST/HR index between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
Time frame: Baseline up to Day 15
Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Slope
ST-HR slope is an index of exercise induced ischemia. Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. The highest ST segment/heart rate slope from among all the ECG leads and the X-axis intercept of the associated line were used to generate the maximum slope. Change in maximum ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
Time frame: Baseline up to Day 15
Change From Baseline in X-Axis Intercept of ST-HR Slope
Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. Change in X- axis intercept of ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
Time frame: Baseline up to Day 15
Change From Baseline in Total Exercise Duration
Total exercise duration was defined as the elapsed time between the start of exercise and termination of exercise for severe angina, dyspnea or extreme fatigue assessed during the exercise treadmill test. Change in the duration of exercise between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
Time frame: Baseline up to Day 15
Change From Baseline in Time to Onset of 1 mm ST Segment Depression (Time to Ischemia)
Exercise-induced ischemia was defined as the new development of horizontal or down sloping ST-segment depression (≥ 1 mm at 60 milliseconds after the J point) vs. baseline tracings. Change in time to onset of 1 mm ST depression between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
Time frame: Baseline up to Day 15
Change From Baseline in Time to Onset of Angina
Time to onset of angina was defined as the elapsed time between the start of exercise and the onset of anginal chest pain as reported by the participant. Change in time to angina between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
Time frame: Baseline up to Day 15
A total of 14 participants took part in the study from 9 March 2012 to 2 January 2014.
| Milestone | Ranolazine 500 mg |
|---|---|
| Started | 14 |
| Completed | 14 |
| Not completed | 0 |
ST/HR index was measured as the average change in ST segment depression relative to heart rate change over the entire duration of exercise, monitored by ECG during the exercise treadmill tests. Change in maximum ST/HR index between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
| microvolts/beats per minute (microV/bpm) | Ranolazine 500 mg |
|---|---|
| Test 1 | 3.211 ± 1.6553 |
| Test 2 | 2.822 ± 1.0289 |
| Test 3 | 3.228 ± 1.8910 |
| Test 4 | 2.502 ± 1.8884 |
| Change From Baseline in Maximum ST/Heart Rate Index | -0.605 ± 1.0482 |
ST-HR slope is an index of exercise induced ischemia. Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. The highest ST segment/heart rate slope from among all the ECG leads and the X-axis intercept of the associated line were used to generate the maximum slope. Change in maximum ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
| microvolts/beat/minute (microV/beat/min) | Ranolazine 500 mg |
|---|---|
| Test 1 | 4.857 ± 2.3042 |
| Test 2 | 5.318 ± 3.0996 |
| Test 3 | 4.645 ± 2.2869 |
| Test 4 | 3.430 ± 2.7374 |
| Change From Baseline in Maximum ST/Heart Rate Slope | -1.553 ± 3.1200 |
Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. Change in X- axis intercept of ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
| beats per minute (bpm) | Ranolazine 500 mg |
|---|---|
| Test 1 | 93.4 ± 21.33 |
| Test 2 | 88.1 ± 27.30 |
| Test 3 | 89.8 ± 19.39 |
| Test 4 | 89.2 ± 24.34 |
| Change From Baseline in X-axis Intercept of ST/Heart Rate Slope | 2.173 ± 8.7326 |
Total exercise duration was defined as the elapsed time between the start of exercise and termination of exercise for severe angina, dyspnea or extreme fatigue assessed during the exercise treadmill test. Change in the duration of exercise between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
| minutes | Ranolazine 500 mg |
|---|---|
| Test 1 | 11.118 ± 3.3519 |
| Test 2 | 11.008 ± 3.3765 |
| Test 3 | 11.150 ± 3.4652 |
| Test 4 | 11.892 ± 3.7094 |
| Change From Baseline in Total Exercise Duration | 0.755 ± 0.9834 |
Exercise-induced ischemia was defined as the new development of horizontal or down sloping ST-segment depression (≥ 1 mm at 60 milliseconds after the J point) vs. baseline tracings. Change in time to onset of 1 mm ST depression between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
| minutes | Ranolazine 500 mg |
|---|---|
| Test 1 | 8.611 ± 3.8054 |
| Test 2 | 8.833 ± 3.2241 |
| Test 3 | 9.196 ± 3.6141 |
| Test 4 | 9.343 ± 4.1114 |
| Change From Baseline in Time to Onset of 1 mm ST Depression | 0.876 ± 1.0227 |
Time to onset of angina was defined as the elapsed time between the start of exercise and the onset of anginal chest pain as reported by the participant. Change in time to angina between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.
| minutes | Ranolazine 500 mg |
|---|---|
| Test 1 | 8.693 ± 2.4635 |
| Test 2 | 7.575 ± 1.9806 |
| Test 3 | 8.189 ± 1.5457 |
| Test 4 | 8.037 ± 3.6395 |
| Change From Baseline in Time to Onset of Angina | 0.473 ± 3.3342 |
Collected over From Baseline up to end of study, approximately 21 days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranolazine 500 mg | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Event | Ranolazine 500 mg |
|---|---|
| NAUSEAGastrointestinal disorders | 1/14 |
| DIZZINESSNervous system disorders | 1/14 |
| HaematuriaRenal and urinary disorders | 1/14 |
| NIGHT SWEATSSkin and subcutaneous tissue disorders | 1/14 |
Safety Analysis Set included all enrolled participants who met the inclusion/exclusion criteria and had at least one post-baseline assessment.
| Age, Continuous(years) | Ranolazine 500 mg |
|---|---|
| Mean | 64.0 ± 7.75 |
| Sex: Female, Male(Participants) | Ranolazine 500 mg |
|---|---|
| Female | 4 |
| Male | 10 |
Ran from Mar 2012 to primary completion in Jan 2014, 21 months.
Results were first posted in Jun 2021, 7 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine